Investment Analysts’ Recent Ratings Changes for Axsome Therapeutics (AXSM)

Axsome Therapeutics (NASDAQ: AXSM) recently received a number of ratings updates from brokerages and research firms:

• 1/6/2026 – Axsome Therapeutics had its price target raised by analysts at UBS Group AG from $163.00 to $248.00. They now have a “buy” rating on the stock.
• 1/5/2026 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $225.00 price target on the stock.
• 1/5/2026 – Axsome Therapeutics had its price target raised by analysts at HC Wainwright from $185.00 to $200.00. They now have a “buy” rating on the stock.
• 1/2/2026 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $205.00 price target on the stock.
• 12/31/2025 – Axsome Therapeutics was given a new $217.00 price target on by analysts at Mizuho.
• 12/31/2025 – Axsome Therapeutics had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $220.00 price target on the stock.
• 12/31/2025 – Axsome Therapeutics had its “overweight” rating reaffirmed by analysts at Morgan Stanley.
• 12/31/2025 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at Cowen Inc.
• 12/31/2025 – Axsome Therapeutics had its price target raised by analysts at Needham & Company LLC from $154.00 to $169.00. They now have a “buy” rating on the stock.

Insider Activity at Axsome Therapeutics

In other news, CEO Herriot Tabuteau sold 91,705 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $132.34, for a total transaction of $12,136,239.70. Following the completion of the sale, the chief executive officer owned 7,229 shares in the company, valued at $956,685.86. This represents a 92.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Mark E. Saad sold 37,577 shares of the business’s stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $165.18, for a total transaction of $6,206,968.86. Following the sale, the director owned 10,002 shares in the company, valued at $1,652,130.36. The trade was a 78.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 281,489 shares of company stock worth $39,671,220 over the last quarter. Company insiders own 22.40% of the company’s stock.

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.